Serum hepcidin concentration is lower in advanced stages of sporadic colorectal cancer
Biochemia medica · 2025
DOI: 10.11613/bm.2025.030703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemia medica, 2025. Verfasst von Tara Rolić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Osijek, Osijek, Croatia. Hauptthemen laut MEDLINE: Hepcidins, Colorectal Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Hepcidin (Hep), a key regulatory hormone of iron (Fe) homeostasis, governs its absorption and storage, and is influenced by inf lammation and Fe status. This study investigated serum Hep concentrations and their associations with Fe markers and inflammation in patients with sporadic colorectal cancer (CRC). Materials and methods: We compared serum concentrations of Hep, Fe, unsaturated and total iron binding capacity, transferrin, transferrin saturation, ferritin, C-reactive protein (CRP), interleukin-6 (IL-6) and tumor markers in 82 CRC patients and 58 controls. Statistically significant differences were tested using the Mann-Whitney U test and Student’s t test. Additionally, Hep were analyzed according to tumor stage. Colorectal cancer was confirmed histopathologically after colonoscopy with biopsy (TNM staging).
Results
Colorectal cancer patients exhibited significantly lower Hep concentrations than controls (8.1 vs. 19.7 ng/mL, P = 0.020). Ferritin was also lower in CRC (109 vs. 250 µg/L, P = 0.002). Hepcidin showed the strongest positive correlation with ferritin in CRC. Inflammatory markers (CRP and IL-6) correlated moderately to weakly with hepcidin in both groups (controls: rho = 0.52 (P < 0.001); CRC: rho = 0.26 (P = 0.022) for CRP and CRC: rho = 0.30 (P = 0.033) for IL-6). Notably, Hep concentrations were lower in patients with advanced tumor stage (T0 vs. T3, P = 0.043).
Conclusion
These findings suggest that CRC is associated with lower hepcidin and ferritin concentrations, potentially reflecting complex and cancer-specific dysregulation in Fe metabolism beyond inflammation alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Osijek, Osijek, Croatia.
- Institute of Clinical Laboratory Diagnostics, Osijek University Hospital Centre, Osijek, Croatia.
- Medical-biochemistry laboratory, Policlinic LabPlus, Osijek, Croatia.
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
- Clinical Institute for Transfusion Medicine, Osijek University Hospital Centre, Osijek, Croatia.
- Faculty of Food Technology Osijek, University of Osijek, Osijek, Croatia.
Zitieren
APA
Rolić, T., Mandić, S., Yazdani, M., Ferenac Kiš, M., Distante, S., & Banjari, I. (2025). Serum hepcidin concentration is lower in advanced stages of sporadic colorectal cancer. Biochemia medica. https://doi.org/10.11613/bm.2025.030703
Vancouver
Rolić T, Mandić S, Yazdani M, Ferenac Kiš M, Distante S, Banjari I. Serum hepcidin concentration is lower in advanced stages of sporadic colorectal cancer. Biochemia medica. 2025. doi:10.11613/bm.2025.030703
BibTeX
@article{Roli2025,
author = {Rolić, Tara and Mandić, Sanja and Yazdani, Mazyar and Ferenac Kiš, Marina and Distante, Sonia and Banjari, Ines},
title = {Serum hepcidin concentration is lower in advanced stages of sporadic colorectal cancer},
journal = {Biochemia medica},
year = {2025},
doi = {10.11613/bm.2025.030703}
}
EUVIMED